ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 given weekly; to characterize the toxicities of ABI-009; and to determine the pharmacokinetic parameters for ABI-009 when given on a weekly schedule.
Solid Tumors
DRUG: ABI-009
Determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 administered weekly and pharmacokinetic parameters for ABI-009., End of Study (EOS) and Follow Up
Efficacy of ABI-009 in this patient population, End of Study (EOS) and Follow Up
No extended description necessary